MDT

86.08

+0.56%↑

A

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

MDT

86.08

+0.56%↑

A

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

MDT

86.08

+0.56%↑

A

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

MDT

86.08

+0.56%↑

A

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

MDT

86.08

+0.56%↑

A

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

Search

Twist Bioscience Corp

Fechado

SetorSaúde

59.76 6.37

Visão Geral

Variação de preço das ações

24h

Atual

Mín

56.18

Máximo

61.55

Indicadores-chave

By Trading Economics

Rendimento

-3.4M

-31M

Vendas

4.7M

104M

Margem de lucro

-29.419

Funcionários

979

EBITDA

-3.2M

-24M

Recomendações

By TipRanks

Recomendações

Compra Forte

Previsão para 12 meses

-2.54% downside

Dividendos

By Dow Jones

Próximos Ganhos

4 de mai. de 2026

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

487M

3.1B

Abertura anterior

53.39

Fecho anterior

59.76

Sentimento de Notícias

By Acuity

50%

50%

162 / 348 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Very Strong Bearish Evidence

Twist Bioscience Corp Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

17 de abr. de 2026, 20:26 UTC

Aquisições, Fusões, Aquisições de Empresas

UCB to Buy Neurona Therapeutics for Up to $1.15 Billion

17 de abr. de 2026, 18:15 UTC

Notícias Principais

Fed's Waller: Prolonged Iran Conflict Could Block Path to Rate Cuts

17 de abr. de 2026, 16:49 UTC

Notícias Principais

Week Ahead for FX, Bonds: U.S. Retail Sales, PMI -2-

17 de abr. de 2026, 16:49 UTC

Notícias Principais

Week Ahead for FX, Bonds: U.S. Retail Sales, PMI Data Due as Focus Remains on Middle East

17 de abr. de 2026, 22:58 UTC

Ganhos

Grupo Aeroportuario Del Pacifico: Announces Filing of 2025 Annual Report and Form 20-F

17 de abr. de 2026, 21:32 UTC

Conversa de Mercado

Cerebras IPO Adds to Big Year For AI Firms Going Public -- Market Talk

17 de abr. de 2026, 21:22 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

17 de abr. de 2026, 21:22 UTC

Conversa de Mercado

Moody's Downgrades Belgium to A1 -- Market Talk

17 de abr. de 2026, 20:52 UTC

Ganhos

Schwab Investors Get Spooked by JPMorgan's AI Strategy. The Big Worry Is Cash Sweeps. -- Barrons.com

17 de abr. de 2026, 20:50 UTC

Conversa de Mercado
Ganhos
Aquisições, Fusões, Aquisições de Empresas

Tech, Media & Telecom Roundup: Market Talk

17 de abr. de 2026, 20:50 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

17 de abr. de 2026, 20:29 UTC

Ganhos

These Stocks Are Today's Movers: Royal Caribbean, Dow Inc., Netflix, Intel, Albemarle, Autoliv, Alcoa, and More -- Barrons.com

17 de abr. de 2026, 20:11 UTC

Aquisições, Fusões, Aquisições de Empresas

UCB to Buy Neurona Therapeutics for Up to $1.15B

17 de abr. de 2026, 19:34 UTC

Conversa de Mercado
Ganhos
Aquisições, Fusões, Aquisições de Empresas

Global Equities Roundup: Market Talk

17 de abr. de 2026, 19:34 UTC

Conversa de Mercado
Ganhos
Aquisições, Fusões, Aquisições de Empresas

Analysts See Netflix's Deal Commentary as Notable -- Market Talk

17 de abr. de 2026, 19:31 UTC

Conversa de Mercado
Notícias Principais

Oil Futures Fall on Reopening of Strait of Hormuz -- Market Talk

17 de abr. de 2026, 19:26 UTC

Conversa de Mercado

U.S. Natural Gas Futures Edge Up -- Market Talk

17 de abr. de 2026, 19:21 UTC

Conversa de Mercado

Albemarle's Outperformance Belies Longer-Term Risks -- Market Talk

17 de abr. de 2026, 19:15 UTC

Conversa de Mercado

Danaher Seen Rebounding in 2H After Tools-Sector Weakness -- Market Talk

17 de abr. de 2026, 19:07 UTC

Conversa de Mercado

Danaher Faces Tough Comparative but Long‑Term Story Intact -- Market Talk

17 de abr. de 2026, 18:57 UTC

Notícias Principais

U.S. Stocks Surge on Hope Iran War Nearing End. Foreign Leaders Have a More Sober View. -- Barrons.com

17 de abr. de 2026, 18:53 UTC

Aquisições, Fusões, Aquisições de Empresas

UCB Expects 2026 Adjusted Ebitda Growth in High Single-Digit to Mid-Teens Percentage Range at Constant Exchange Rates

17 de abr. de 2026, 18:53 UTC

Aquisições, Fusões, Aquisições de Empresas

UCB 2026 Rev Guidance Unchanged

17 de abr. de 2026, 18:52 UTC

Aquisições, Fusões, Aquisições de Empresas

UCB: Neurona Deal to Include $650M Upfront and Up to $500M in Potential Future Milestones

17 de abr. de 2026, 18:52 UTC

Aquisições, Fusões, Aquisições de Empresas

UCB to Acquire Neurona Therapeutics for Up to $1.15B Including Potential Milestones

17 de abr. de 2026, 18:14 UTC

Conversa de Mercado
Notícias Principais

Precious Metals Close Higher as Stronger Demand Eyed -- Market Talk

17 de abr. de 2026, 18:00 UTC

Notícias Principais

Fed's Waller: Quick Resolution in Middle East Could Allow Cuts Later This Year

17 de abr. de 2026, 18:00 UTC

Notícias Principais

Fed's Waller: Job Losses May Not Signal Recession Amid Demographic Changes

17 de abr. de 2026, 17:31 UTC

Conversa de Mercado
Notícias Principais

U.S. Oil Rig Count Down By 1 at 410 -- Market Talk

17 de abr. de 2026, 17:26 UTC

Conversa de Mercado
Ganhos

Netflix's Ability to Grow Engagement Seen as Up in the Air -- Market Talk

Comparação entre Pares

Variação de preço

Twist Bioscience Corp Previsão

Preço-alvo

By TipRanks

-2.54% parte inferior

Previsão para 12 meses

Média 54.8 USD  -2.54%

Máximo 58 USD

Mínimo 50 USD

Com base em 6 analistas de Wall Street que oferecem metas de preço de 12 meses para Twist Bioscience Corp - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

6 ratings

6

Comprar

0

Manter

0

Vender

Pontuação Técnica

By Trading Central

31.56 / 38.6884Suporte e Resistência

Curto Prazo

Very Strong Bearish Evidence

Médio Prazo

Bearish Evidence

Longo Prazo

Bearish Evidence

Sentimento

By Acuity

162 / 348 Ranking em Saúde

Sentimento de Notícias

Neutral

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Twist Bioscience Corp

Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, it offers synthetic SARS-CoV-2 RNA reference sequences as positive controls to develop both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company has a strategic collaboration with bitBiome Inc. The company was incorporated in 2013 and is headquartered in South San Francisco, California.
help-icon Live chat